📊 DNTH Key Takeaways
Is Dianthus Therapeutics, Inc. /DE/ (DNTH) a Good Investment?
Dianthus Therapeutics is a pre-revenue stage biopharmaceutical company burning $29M annually with minimal $2M revenue and massive operating losses (-2285% margin). While the $628M cash position and negligible debt provide 20+ years of runway, the complete absence of profitable operations and commercial traction presents substantial fundamental weakness for a company at this stage of development.
Dianthus Therapeutics shows very weak current fundamentals, with minimal revenue, deeply negative operating and net margins, and heavy ongoing cash burn. The balance sheet is a clear strength because the company has substantial equity, strong liquidity, and no meaningful leverage, but the business remains dependent on converting R&D spending into future commercial progress.
Dianthus Therapeutics, Inc. /DE/ Key Strengths (DNTH)
- Exceptional liquidity with $628M cash against $46M liabilities (13.8x ratio)
- Zero long-term debt and minimal financial obligations reduce capital structure risk
- Strong balance sheet ($1.2B assets) with 20+ year cash runway at current burn rate
- Very strong liquidity with current and quick ratios of 13.32x
- Large equity base and low liabilities support balance-sheet resilience
- No meaningful long-term debt reduces financial distress risk
DNTH Stock Risks: Dianthus Therapeutics, Inc. /DE/ Investment Risks
- Extreme unprofitability: -$46.5M operating loss and -$40.8M net loss on $2M revenue
- Negative free cash flow of -$29.1M annually indicating pure R&D spend with no commercial validation
- Early-stage biotech with minimal revenue suggests pipeline execution risk and regulatory approval uncertainty
- Extremely weak profitability, including operating margin of -8739.3% and net margin of -7973.3%
- Large negative operating cash flow and free cash flow indicate sustained cash burn
- Revenue base is negligible, so growth quality and business model durability remain unproven
Key Metrics to Watch
- Monthly cash burn rate and cash runway extension
- Revenue growth trajectory and product approval milestones
- Operating cash flow improvement toward breakeven
- Clinical pipeline advancement and trial success rates
- Quarterly operating cash burn relative to cash and equivalents
- Meaningful revenue growth and improvement in operating loss
Dianthus Therapeutics, Inc. /DE/ (DNTH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 29.25x current ratio provides a solid financial cushion.
DNTH Profit Margin, ROE & Profitability Analysis
DNTH vs Healthcare Sector: How Dianthus Therapeutics, Inc. /DE/ Compares
How Dianthus Therapeutics, Inc. /DE/ compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Dianthus Therapeutics, Inc. /DE/ Stock Overvalued? DNTH Valuation Analysis 2026
Based on fundamental analysis, Dianthus Therapeutics, Inc. /DE/ has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Dianthus Therapeutics, Inc. /DE/ Balance Sheet: DNTH Debt, Cash & Liquidity
DNTH Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Dianthus Therapeutics, Inc. /DE/'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.55 indicates the company is currently unprofitable.
DNTH Revenue Growth, EPS Growth & YoY Performance
DNTH Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $396.0K | -$13.7M | $-0.74 |
| Q2 2025 | $193.0K | -$13.7M | $-0.51 |
| Q1 2025 | $874.0K | -$13.7M | $-0.54 |
| Q3 2023 | $924.0K | -$4.9M | $-3.78 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Dianthus Therapeutics, Inc. /DE/ Dividends, Buybacks & Capital Allocation
DNTH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Dianthus Therapeutics, Inc. /DE/ (CIK: 0001690585)
📋 Recent SEC Filings
❓ Frequently Asked Questions about DNTH
What is the AI rating for DNTH?
Dianthus Therapeutics, Inc. /DE/ (DNTH) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are DNTH's key strengths?
Claude: Exceptional liquidity with $628M cash against $46M liabilities (13.8x ratio). Zero long-term debt and minimal financial obligations reduce capital structure risk. ChatGPT: Very strong liquidity with current and quick ratios of 13.32x. Large equity base and low liabilities support balance-sheet resilience.
What are the risks of investing in DNTH?
Claude: Extreme unprofitability: -$46.5M operating loss and -$40.8M net loss on $2M revenue. Negative free cash flow of -$29.1M annually indicating pure R&D spend with no commercial validation. ChatGPT: Extremely weak profitability, including operating margin of -8739.3% and net margin of -7973.3%. Large negative operating cash flow and free cash flow indicate sustained cash burn.
What is DNTH's revenue and growth?
Dianthus Therapeutics, Inc. /DE/ reported revenue of $2.0M.
Does DNTH pay dividends?
Dianthus Therapeutics, Inc. /DE/ does not currently pay dividends.
Where can I find DNTH SEC filings?
Official SEC filings for Dianthus Therapeutics, Inc. /DE/ (CIK: 0001690585) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is DNTH's EPS?
Dianthus Therapeutics, Inc. /DE/ has a diluted EPS of $-0.85.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is DNTH's fundamental grade?
Based on our AI fundamental analysis in June 2026, Dianthus Therapeutics, Inc. /DE/ has a C grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is DNTH stock overvalued or undervalued?
Valuation metrics for DNTH: ROE of -3.4% (sector avg: 15%), net margin of -2,005.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is DNTH's AI grade for 2026?
Our dual AI analysis gives Dianthus Therapeutics, Inc. /DE/ a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is DNTH's free cash flow?
Dianthus Therapeutics, Inc. /DE/'s operating cash flow is $-28.9M, with capital expenditures of $245.0K. FCF margin is -1,429.3%.
How does DNTH compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2,005.6% (avg: 12%), ROE -3.4% (avg: 15%), current ratio 29.25 (avg: 2).